Publications by authors named "Tamara Fraikin"
Background: The recent introduction of magnetic resonance-guided radiation therapy (MRgRT) has allowed improved treatment planning and delivery of stereotactic body radiotherapy (SBRT) in prostate cancer (PC). The health-related quality of life (HRQoL) outcomes using this novel approach are important in shared decision making for patients.
Objective: To report HRQoL using both patient- and clinician-reported outcomes at 1 yr following stereotactic MRgRT for patients with localized PC.
Article Synopsis
- Stereotactic body radiation therapy (SBRT) is increasingly used for localized prostate cancer, but there are concerns about potential gastrointestinal (GI) and genitourinary (GU) toxicities from intensive radiation methods.
- A phase 2 study involving 101 patients aimed to assess early GI and GU toxicity after administering SBRT using Magnetic Resonance guided Radiation Therapy (MRgRT), which allows for more precise treatment delivery and adaptive planning.
- The results showed that early GU toxicity was at 23.8% and GI toxicity was at 5%, with no instances of grade 3 GI toxicity, highlighting a lower incidence of early adverse effects due to the precision offered by MRgRT.